Glioblastoma (GBM) is the most common primary malignant brain tumor in adults.
Regardless of ideal multidisciplinary treatment, including maximal surgical resection …

Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy,
followed by radiation plus concomitant and adjuvant temozolomide. The treatment of …

Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in
the United States for recurrent GBM in 2009. In order to review the therapeutic effect of …

Although vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) is traditionally
regarded as an endothelial cell protein, evidence suggests that VEGFRs may be expressed …

Introduction Standards of care are not yet defined in recurrent glioblastoma. Methods We
reviewed the literature on clinical trials for recurrent glioblastoma available in PubMed and …

Metronomic chemotherapy, continuous and dose‐dense administration of chemotherapeutic
drugs with lowered doses, is being evaluated for substituting, augmenting, or appending …

Glioblastoma (GBM) is the most common and lethal intracranial malignancy, with few
advances in treatment over the last several decades. Much excitement surrounded the initial …

External beam radiotherapy (RT) has long played a crucial role in the treatment of
glioblastoma. Over the past several decades, significant advances in RT treatment and …

Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor in adults
with generally dismal prognosis, early clinical deterioration and high mortality. GBM is …

BACKGROUND: The authors performed a phase 2 trial of combined protracted daily
temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had …